S

eeking to stem its own opioid crisis, the Canadian government announced plans to restrict marketing of the addictive painkillers by the pharmaceutical industry to physicians.

Among the steps the health ministry envisions is requiring drug makers to develop and implement risk management plans, which would mean that companies would have to obtain clearance for materials provided to doctors in order to ensure advertising complies with marketing authorization.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy